Please ensure Javascript is enabled for purposes of website accessibility

Why Aurinia Pharmaceuticals Dived by 16% on Thursday

By Eric Volkman – Jul 23, 2020 at 5:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors weren't happy to hear about a new share issue from the Canadian biotech.

What happened

One day after moving higher in the market, Aurinia Pharmaceuticals (AUPH 0.94%) stock was deep in the loss column on Thursday. Optimism flowing from good news the previous day was erased by the Canadian biotech's announcement that it's floating a new, $200 million secondary stock issue consisting of slightly over 13.3 million common shares.

So what

Aurinia's motives for this fresh round of capital-raising seem pure. The company says it will utilize the proceeds from the issue chiefly "for pre-commercialization and launch activities, research and development" for its pipeline drug Lupus Nephritis treatment Voclosporin. The company's good Wednesday news was that Voclosporin's New Drug Application (NDA) filing was accepted by the Food and Drug Administration (FDA).

A doctor discussing matters with another person.

Image source: Getty Images.

Voclosporin is now set to be the first approved treatment for the affliction, which is a serious inflammation resulting from systemic lupus erythematosus (an autoimmune disorder).

The problem with the share issue is dilution. According to statistics compiled by Yahoo! Finance, Aurinia currently has slightly over 112.6 million shares of common stock outstanding. As a result, the new issue's dilution will edge into the double digits, at a bit over 10% of the current count.

Now what

Investors might be overreacting to the latest news. The FDA has granted Voclosporin priority review, with a target-action date of Jan. 22, 2021. That's very soon by pharmaceutical-industry standards, so if the drug gets the green light, Aurinia could have a blockbuster product on the market within only a few quarters.  

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurinia Pharmaceuticals Inc. Stock Quote
Aurinia Pharmaceuticals Inc.
$7.52 (0.94%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.